Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, Kulke M, Pavel ME, Yao JC (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Book Volume: 106
Pages Range: 211-211
Authors with CRIS profile
Involved external institutions
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Novartis AG
Switzerland (CH)
Novartis Pharma S.A.S.
France (FR)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Istituto Clinico Humanitas
Italy (IT)
University of Manchester
United Kingdom (GB)
Dana–Farber Cancer Institute
United States (USA) (US)
Italy (IT)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Novartis AG
Switzerland (CH)
Novartis Pharma S.A.S.
France (FR)
H. Lee Moffitt Cancer Center & Research Institute
United States (USA) (US)
Istituto Clinico Humanitas
Italy (IT)
University of Manchester
United Kingdom (GB)
Dana–Farber Cancer Institute
United States (USA) (US)
How to cite
APA:
Fazio, N., Carnaghi, C., Buzzoni, R., Valle, J., Herbst, F., Ridolfi, A.,... Yao, J.C. (2018). Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials. (pp. 211-211).
MLA:
Fazio, N., et al. "Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials." 2018. 211-211.
BibTeX: Download